Retatrutide in Type 2 Diabetes: Triple Agonist Delivers Powerful HbA1c and Weight Reduction: The Lancet | June 2026

• Retatrutide is a once-weekly injectable triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors.

• TRANSCEND-T2D-1 evaluated retatrutide as monotherapy in adults with type 2 diabetes inadequately controlled with diet and exercise alone.

• The study included 537 patients with early type 2 diabetes, mean HbA1c of 7.9%, mean diabetes duration of 2.5 years, and mean BMI of 35.8 kg/m².

• Retatrutide produced significant HbA1c reductions at all tested doses compared with placebo.

• Mean HbA1c reduction at 40 weeks was –1.69% with 4 mg, –1.86% with 9 mg, and –1.94% with 12 mg, compared with –0.81% with placebo.

• Weight loss was substantial and dose-related, which is especially relevant because weight reduction is often harder to achieve in patients with type 2 diabetes.

• Mean bodyweight reduction was –11.5% with 4 mg, –13.9% with 9 mg, and –15.3% with 12 mg, compared with –2.6% with placebo.

• The magnitude of weight loss suggests that retatrutide may become important not only for glycaemic control, but also for obesity-driven metabolic disease.

• No severe hypoglycaemia was reported, which is reassuring for a therapy used without insulin or sulfonylureas.

• The most common adverse events were gastrointestinal, generally mild to moderate, and tended to reduce over time.

• Treatment discontinuation due to adverse events was low, occurring in 2%–5% of retatrutide-treated patients.

• The study population had relatively early diabetes and was not on background glucose-lowering therapy, so results may not directly apply to patients with long-standing or insulin-treated diabetes.

• Long-term cardiovascular, renal, hepatic, and real-world tolerability data will be important before defining its exact place in therapy.

• For gastroenterologists, the key relevance is the broader metabolic impact: powerful weight loss may influence future management of MASLD, obesity-related GI disease, and cardiometabolic risk.

Bottom line: Retatrutide produced impressive dual benefits in early type 2 diabetes—nearly 2% HbA1c reduction and up to 15% bodyweight loss over 40 weeks—supporting its potential as a major next-generation metabolic therapy.